About: Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First-in-class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM, both in pre-clinical and in clinical studies. However, despite its high efficiency, a large proportion of patients do not achieve sufficient clinical response. Therefore, the development of a second-generation of proteasome inhibitors (PIs) with improved pharmacological properties was needed. Recently, several of these new agents have been introduced into clinics including carfilzomib, marizomib and ixazomib. Further, new orally administered second-generation PI oprozomib is being investigated. This review provides an overview of main mechanisms of action of PIs in MM, focusing on the ongoing development and progress of novel anti-proteasome therapeutics. Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First-in-class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM, both in pre-clinical and in clinical studies. However, despite its high efficiency, a large proportion of patients do not achieve sufficient clinical response. Therefore, the development of a second-generation of proteasome inhibitors (PIs) with improved pharmacological properties was needed. Recently, several of these new agents have been introduced into clinics including carfilzomib, marizomib and ixazomib. Further, new orally administered second-generation PI oprozomib is being investigated. This review provides an overview of main mechanisms of action of PIs in MM, focusing on the ongoing development and progress of novel anti-proteasome therapeutics. (en)
Title	Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma (en)
skos:prefLabel	Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma (en)
skos:notation	RIV/00216224:14110/14:00075479!RIV15-MSM-14110___
http://linked.open...avai/riv/aktivita	I P Z
http://linked.open...avai/riv/aktivity	I, P(7E12070), Z(MSM0021622434)
http://linked.open...iv/cisloPeriodika	6
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Pour, Luděk Ševčíková, Sabina Hájek, Roman Kubiczková, Lenka Sedlaříková, Lenka
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	40449
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/14:00075479
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Bortezomib; Multiple myeloma; New-generation proteasome inhibitors (en)
http://linked.open.../riv/klicoveSlovo	Bortezomib Multiple myeloma New-generation proteasome inhibitors
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[4804EF31C82A]
http://linked.open...i/riv/nazevZdroje	Journal of Cellular and Molecular Medicine
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	5 (xsd:int)
http://linked.open...cetTvurcuVysledku	5 (xsd:int)
http://linked.open...vavai/riv/projekt	Optimizing targets and therapeutics in high risk and refractory multiple myeloma
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	18
http://linked.open...iv/tvurceVysledku	Hájek, Roman Pour, Luděk Ševčíková, Sabina Kubiczková, Lenka Sedlaříková, Lenka
http://linked.open...ain/vavai/riv/wos	000340390500001
http://linked.open...n/vavai/riv/zamer	From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
issn	1582-4934
number of pages	15 (xsd:int)
http://bibframe.org/vocab/doi	10.1111/jcmm.12279
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software